Glucagon-like peptide-1 receptor agonists and the eye.

IF 3 2区医学 Q1 OPHTHALMOLOGY

Current Opinion in Ophthalmology Pub Date : 2025-03-27 DOI:10.1097/ICU.0000000000001137

David L Zhang, Avni P Finn

{"title":"Glucagon-like peptide-1 receptor agonists and the eye.","authors":"David L Zhang, Avni P Finn","doi":"10.1097/ICU.0000000000001137","DOIUrl":null,"url":null,"abstract":"Purpose of review: Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown. This review aims to consolidate the existing evidence on the effects of GLP-1RA on conditions such as diabetic retinopathy (DR), nonarteritic ischemic optic neuropathy (NAION), glaucoma, age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH), and dry eye disease (DED).Recent findings: The effect of GLP-1RA on DR is controversial but likely linked to rapid correction of hemoglobin A1c levels. GLP-1RA may be associated with increased risk of NAION, although the mechanism remains elusive. Protective effects have been shown against glaucoma, AMD, and DED possibly due to its anti-inflammatory properties, and these medications may decrease intracranial pressure in IIH.Summary: As the usage of GLP-1RA increases, further dedicated ocular safety trials are key to determining the risk of eye-related complications. Given the limited prospective evidence available and the proven systemic benefits of the medication, as well as its potential protective effects on certain eye diseases, GLP-1RA use should generally not be discouraged in most patients. Regular ophthalmologic follow up is important in patients considered at higher risk of ocular adverse events.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICU.0000000000001137","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown. This review aims to consolidate the existing evidence on the effects of GLP-1RA on conditions such as diabetic retinopathy (DR), nonarteritic ischemic optic neuropathy (NAION), glaucoma, age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH), and dry eye disease (DED).

Recent findings: The effect of GLP-1RA on DR is controversial but likely linked to rapid correction of hemoglobin A1c levels. GLP-1RA may be associated with increased risk of NAION, although the mechanism remains elusive. Protective effects have been shown against glaucoma, AMD, and DED possibly due to its anti-inflammatory properties, and these medications may decrease intracranial pressure in IIH.

Summary: As the usage of GLP-1RA increases, further dedicated ocular safety trials are key to determining the risk of eye-related complications. Given the limited prospective evidence available and the proven systemic benefits of the medication, as well as its potential protective effects on certain eye diseases, GLP-1RA use should generally not be discouraged in most patients. Regular ophthalmologic follow up is important in patients considered at higher risk of ocular adverse events.

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂与眼睛。

综述目的：胰高血糖素样肽-1受体激动剂（GLP-1RA）作为一种具有心血管保护作用的降糖和减肥药物已经得到了广泛的应用，但对其潜在的眼部副作用的关注也越来越多。本综述旨在巩固GLP-1RA对糖尿病视网膜病变（DR）、非动脉性缺血性视神经病变（NAION）、青光眼、年龄相关性黄斑变性（AMD）、特发性颅内高压（IIH）和干眼病（DED）等疾病的作用的现有证据。最近的发现：GLP-1RA对DR的影响是有争议的，但可能与快速纠正血红蛋白A1c水平有关。GLP-1RA可能与NAION风险增加有关，但其机制尚不明确。对青光眼、AMD和DED的保护作用可能是由于其抗炎特性，这些药物可能降低IIH患者的颅内压。摘要：随着GLP-1RA使用的增加，进一步专门的眼部安全性试验是确定眼部相关并发症风险的关键。鉴于有限的前瞻性证据和已证实的药物系统性益处，以及其对某些眼病的潜在保护作用，大多数患者通常不应劝阻使用GLP-1RA。定期眼科随访对于有较高眼部不良事件风险的患者很重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Ophthalmology 医学-眼科学

CiteScore

6.80

自引率

5.40%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Ophthalmology is an indispensable resource featuring key up-to-date and important advances in the field from around the world. With renowned guest editors for each section, every bimonthly issue of Current Opinion in Ophthalmology delivers a fresh insight into topics such as glaucoma, refractive surgery and corneal and external disorders. With ten sections in total, the journal provides a convenient and thorough review of the field and will be of interest to researchers, clinicians and other healthcare professionals alike.